Anorexia-Cachexia Syndrome (CS) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Cachexia Syndrome (CS) is a multifactorial syndrome characterized by body weight loss, declining muscle mass and function, wasting, and inflammation of adipose tissues accompanied by metabolic dis-arrangement, anorexia, systemic inflammation, and insulin resistance. The clinical relevance of cachexia is shown by its impact on both the prognosis and the efficacy of treatment against the underlying disease and survival time and quality of life. Cachexia is typically associated with several underlying chronic degenerative diseases, such as cancer, chronic obstructive pulmonary disease (COPD), HIV, chronic heart failure, diabetes, liver failure, rheumatoid arthritis, and chronic kidney failure. Chronic conditions share several underlying mechanisms and ultimately have similar output, i.e., severe muscle wasting. However, the multifactorial origin of cachexia and its multisystem involvement made the study of this syndrome in the context of underlying chronic diseases. This is also characterized by an ongoing loss of skeletal muscle that cannot be fully reversed by conventional nutritional support, leading to progressive functional impairment.

 

The overall prevalence of Cachexia is ranged between 0.19% to 0.23% in the USA, and in the EU, the overall prevalence ranges between 0.28% to 0.32%.

The competitive landscape of Anorexia-Cachexia Syndrome (CS) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Anorexia-Cachexia Syndrome (CS) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Anorexia-Cachexia Syndrome (CS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Anorexia-Cachexia Syndrome (CS) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Anamorelin Hydrochloride          Helsinn Healthcare SA   Phase 3

2          PF-06946860    Pfizer    Phase 1

3          Megestrol acetate          Endo Pharmaceuticals   Phase 2

4          Ruxolitinib         Incyte Corporation         Early Phase 1

5          Xilonix   Janssen Research & Development, LLC Phase 3

6          Remune            Smartfish AS     Phase 1